GRM3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Eglumetad (SCHEMBL231157)	1.00	14/20
SCHEMBL233370	0.73	14/20
SCHEMBL169075	0.43	7/20
SCHEMBL231038	0.80	6/20
SCHEMBL232984	0.56	6/20
SCHEMBL232985	0.55	6/20
SCHEMBL230995	0.77	5/20
SCHEMBL160783	0.54	5/20
SCHEMBL192230	0.51	5/20
SCHEMBL179722	0.47	5/20
SCHEMBL158843	1.00	4/20
SCHEMBL179741	1.00	4/20
SCHEMBL234576	1.00	4/20
SCHEMBL235442	1.00	4/20
SCHEMBL232371	0.83	4/20
Hydrochloric Acid (SCHEMBL232370)	0.81	4/20
SCHEMBL231526	0.80	4/20
Hydrochloric Acid (SCHEMBL231525)	0.79	4/20
SCHEMBL232418	0.79	4/20
SCHEMBL233677	0.77	4/20

Clinical trials — most relevant to GRM3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pilot Study: Postoperative Pain Reduction by Pre Emptive N-Acetylcysteine	PHASE4	COMPLETED
Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine	PHASE4	COMPLETED
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders	PHASE3	RECRUITING
Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome	PHASE3	UNKNOWN
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)	PHASE2/PHASE3	RECRUITING
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial	PHASE2/PHASE3	NOT_YET_RECRUITING
Memantine for Refractory OCD Patients	PHASE3	UNKNOWN
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia	PHASE2	COMPLETED
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders	PHASE2	COMPLETED
TRPM8 Activators for Peripheral Neuropathy	PHASE2	ACTIVE_NOT_RECRUITING
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia	PHASE2	UNKNOWN
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder	PHASE2	COMPLETED
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203	PHASE1	COMPLETED
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia	PHASE1	COMPLETED
Evaluation of Two Radioactive Chemicals to Image mGluR5 Receptors in Brain	PHASE1	COMPLETED
Brain Imaging, Genetics and Treatment for Major Depression	PHASE1	WITHDRAWN
A Study of [11C]JNJ-42491293, a Possible PET Ligand for the mGlu2 Receptor, in Healthy Adult Volunteers	PHASE1	COMPLETED
Antidepressant Effects of NR2B in Major Depression	PHASE1	COMPLETED
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine	EARLY_PHASE1	COMPLETED
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy)	nan	UNKNOWN
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX	nan	COMPLETED
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED
Metabotropic Receptors For Glutamate Type 3 In Parkinson's	nan	UNKNOWN
Acamprosate: Genes Associated With Response	nan	COMPLETED
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy	nan	UNKNOWN
Sleep/Wake Cycle and Depression: An Imaging and Treatment Study	nan	COMPLETED
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Examination of Glutamate and mGluR5 in Psychiatric Disorders	nan	COMPLETED
Epigenetic and Neurochemical Correlates of Bipolar Disorder	nan	NOT_YET_RECRUITING
Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GRM3 binder may also engage these)

Protein	Name	Similarity
Q1ZZH1	—	1.000	Q1ZZH1 →
Q5RAL3	—	1.000	Q5RAL3 →
Q9QYS2	—	1.000	Q9QYS2 →
P31422	—	1.000	P31422 →
GRM5	Metabotropic glutamate receptor 5	1.000	landscape →
GRM1	Metabotropic glutamate receptor 1	1.000	landscape →
Q3UVX5	—	1.000	Q3UVX5 →
P31424	—	0.998	P31424 →
P91685	—	0.997	P91685 →
P97772	—	0.996	P97772 →
P23385	—	0.995	P23385 →
Q09630	—	0.994	Q09630 →
O70410	—	0.992	O70410 →
Q38PU2	—	0.991	Q38PU2 →
Q9Z2W8	—	0.991	Q9Z2W8 →
G5ECB2	—	0.990	G5ECB2 →
B1AS29	—	0.990	B1AS29 →
GRIA2	Glutamate receptor 2	0.989	landscape →
P42264	—	0.989	P42264 →
H2L0Q3	—	0.989	H2L0Q3 →
GRIA4	Glutamate receptor 4	0.988	landscape →
P42260	—	0.987	P42260 →
P39087	—	0.987	P39087 →
P19492	—	0.987	P19492 →
P23819	—	0.987	P23819 →
Q60934	—	0.987	Q60934 →
Q5R4M0	—	0.987	Q5R4M0 →
Q38PU5	—	0.987	Q38PU5 →
P26591	—	0.986	P26591 →
GRIK3	Glutamate receptor ionotropic, kainate 3	0.986	landscape →